MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Corticobasal degeneration (CBD)"

  • 2017 International Congress

    Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease

    J. Etcheverry, M. Cesarini, G. Rojas, E. Gatto (Buenos Aires, Argentina)

    Objective: to determine whether Dextrometorphan/quinidine (DMQ) is effective in the treatment of PBA, AG or bulbar symptoms in corticobasal syndrome (CBS), multiple system atrophy (MSA),…
  • 2017 International Congress

    Blink reflex recovery cycle to differentiate Progressive Supranuclear Palsy from Corticobasal Degeneration

    G. Sciacca, A. Nicoletti, G. Mostile, A. Luca, L. Raciti, V. Dibilio, F. Le Pira, M. Zappia (Catania, Italy)

    Objective: To evaluate R2 Blink Reflex Recovery Cycle (BRRC) in patients with Progressive Supranuclear Palsy (PSP) and CorticoBasal Degeneration (CBD) and to determine its diagnostic…
  • 2017 International Congress

    Corticobasal syndrome due to brain tumor

    P. Tsitsi, G. Xiromerisiou, T. Kalantzakou, T. Bourinaris, G. Deretzi (Stockholm, Sweden)

    Objective: To describe a case of a 60-year-old female that presented with cognitive decline and gait disorders for the last 7 years.   Background: The…
  • 2017 International Congress

    The Corticobasal Degeneration Functional Rating Scale (CBD-FS)

    A. Lang, G. Stebbins, A. Boxer (Toronto, Canada)

    Objective: To develop a patient/care giver-reported scale that is capable of assessing functional disability in CBD that can be easily and reliably used in clinical…
  • 2017 International Congress

    Signal intensity of cerebral gyri in corticobasal degeneration on phase difference enhanced MR images: Comparison with progressive supranuclear palsy and Parkinson’s disease

    M. Miyata, S. Kakeda, T. Yoneda, S. Ide, K. Watanabe, J. Moriya, H. Narimatsu, T. Sato, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

    Objective: We evaluated the signal intensity of the cerebral gyri (CG) on phase difference enhanced imaging (PADRE) for the patients with corticobasal degeneration (CBD), progressive…
  • 2016 International Congress

    A longitudinal observational study of a cohort of patients with PSP/CBD: The JALPAC project

    T. Tokuda, T. Ikeuchi, H. Takigawa, I. Aiba, T. Shimohata, M. Morita, O. Onodera, S. Murayama, K. Nakashima (Kyoto, Japan)

    Objective: To identify PSP/CBD progression biomarkers both to improve understanding of disease etiology and course, and to provide crucial tools to enhance the likelihood of…
  • 2016 International Congress

    “Words untold”

    P.M. Iyer, B. McGuiness, J. Scott, S. Manning, A. Chalisseri, D. Olszewska, M. Farrell, T. Lynch (Dublin, Ireland)

    Objective: To highlight the salient clinical and pathologic features of primary progressive apraxia of speech through a clinical case presentation. Background: Apraxia of speech is…
  • 2016 International Congress

    Dorsal simultanagnosia as a cortical sign in the tauopathy spectrum

    B. Bergmans, O. Deryck, R. Bruffaerts (Brugge, Belgium)

    Objective: Clinical characterization of a tauopathy spectrum patient. Background: In recent years phenotypic overlap has been demonstrated between patients with progressive supranuclear palsy (PSP) pathology…
  • 2016 International Congress

    Overlapping corticobasal syndromes: The many faces of the Armstrong criteria

    A. Pilotto, W. Maetzler, M. Synofzik, E. Schaeffer, C. Schulte, M.A. Hobert, K. Srulijes, T. Gasser, D. Berg (Tübingen, Germany)

    Objective: To evaluate the prevalence and clinical presentation of corticobasal variants listed in the new Armstrong criteria, exploring their overlap with progressive supranuclear palsy (PSP),…
  • 2016 International Congress

    Oxysterol and chitotriosidase as biomarkers for atypical Parkinsonian symptoms?

    M. Schuberth, G. Nübling, J. Hauer, T. Marquardt, S. Lorenzl (München, Germany)

    Objective: The aim of the study is to establish chitotriosidase and oxysterols as a biomarker for atypical Parkinsonian syndromes in order to make a distinction…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley